Jeffrey Lipton, PhD, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, highlights the different tyrosine kinase inhibitors (TKI) available for the treatment of chronic myeloid leukemia (CML), commenting on their efficacy and toxicity, and discussing the management of CML in the third-line setting. Prof. Lipton also outlines novel TKIs under investigation for patients who are resistant to available TKIs. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
